Results 191 to 200 of about 2,262 (235)

Trends in costs and prescribing for liothyronine and levothyroxine in England and wales 2011–2020 [PDF]

Clinical Endocrinology, 2021
IntroductionRecent prescribing policies in England and Wales have imposed significant restrictions on liothyronine prescribing in general practice driven by the prohibitive costs and uncertain benefits of liothyronine in the management of hypothyroidism.
Michael Stedman, Peter Taylor, Colin Dayan   +2 more
exaly   +2 more sources

Liothyronine

Reactions Weekly, 2005
F. Lee Cantrell
core   +3 more sources

Liothyronine (LT3) prescribing in England: Are cost constraints inhibiting guideline implementation? [PDF]

Clinical Endocrinology
Background: Primary hypothyroidism affects about 3% of the general population in Europe. In most cases people with hypothyroidism are treated with levothyroxine.
Michael Stedman, Peter Taylor, Lakdasa Premawardhana   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Liothyronine

Reactions Weekly, 2023
openaire   +1 more source

Liothyronine

Reactions Weekly, 2022
openaire   +2 more sources

Liothyronine

Reactions Weekly, 2019
openaire   +2 more sources

Liothyronine

Reactions Weekly, 2018
  +4 more sources

Liothyronine/levothyroxine sodium/liothyronine overdose

Reactions Weekly, 2020
openaire   +1 more source